News
13h
MedPage Today on MSNDurable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual ImmunotherapyParticipants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...
2d
News-Medical.Net on MSNLong-term survival achieved in stage III melanoma with pre-surgery immunotherapyFour years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...
University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...
The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...
5d
New Scientist on MSNHerpes virus could soon be approved to treat severe skin cancerA cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...
Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.
Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...
FITBOOK magazine on MSN3d
Can Melanoma Soon Be Treated With Herpes Viruses?Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...
Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...
IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results